Positive results of the Phase 2 study evaluating masitinib in Covid-19
08/07/2024 – AB Science today announces the results of a Phase 2 study evaluating masitinib in COVID-19
AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS
28/06/2024 – AB Science today announces that the CHMP has adopted, in line with the trend vote, a negative opinion on the application for conditional marketing authorization of masitinib in the treatment of ALS
June 26, 2024 CGM – Q&A document
26/06/2024 – Q&A document of the June 26, 2024 Combined General Meeting
Summary of the live webcast held on May 30, 2024, giving an update on the application for conditional marketing authorization of masitinib in ALS
31/05/2024 – AB Science is providing a summary of the live webcast held on May 30, 2024, giving an update on the application for conditional marketing authorization of masitinib in ALS
AB Science webcast of May 30, 2024
30/05/2024 – Presentation of the AB Science webcast held on May 30, 2024
AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS
29/05/2024 – AB Science today announces that the CHMP adopted a trending toward a negative opinion on the application for conditional marketing authorisation of masitinib in ALS
Corrective statement on the consolidated accounts as of December 31, 2023
17/05/2024 – AB Science communicates a corrective statement on the consolidated accounts as of December 31, 2023
Annual financial results as of 31 December, 2023
15/05/2024 – AB Science reports its revenues for the year 2023 and provides an update on its activities
AB Science announces issuance of a European patent for masitinib in the treatment of severe mastocytosis with protection until 2036
13/05/2024 – AB Science today announced that the European patent office has issued a Grant Decision for a patent relating to methods of treating severe mastocytosis with its lead compound masitinib
A new publication in the medical journal Muscle & Nerve validates the use of the rate of decline of ALSFR-S score (ΔFS) for the design of clinical studies and the treatment choice for amyotrophic lateral sclerosis (ALS) patients
07/05/2024 – AB Science today announced the publication of an article in Muscle & Nerve, a peer-reviewed medical journal covering neuromuscular medicine